A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck
John A. Vargo(UPMC Hillman Cancer Center), Dwight E. Heron(Bon Secours Mercy Health), Barton F. Branstetter(University of Pittsburgh Medical Center), Umamaheswar Duvvuri(City University of New York), D.A. Clump(UPMC Hillman Cancer Center), James Ohr(University of Pittsburgh), Julie E. Bauman(George Washington University), Robert L. Ferris(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh), Kara S. Davis(University of Pittsburgh), Michael K. Gibson(Vanderbilt University)
International Journal of Radiation Oncology*Biology*Physics
January 30, 2015
Cited by 156
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653